31 results about "Low density lipoprotein cholesterol" patented technology

The invention provides an application of streptococcus salivarius in fatty liver, in particular to an application of streptococcus salivarius in preparation of a product, and the product is used for at least one of the following applications: (a) losing weight or reducing body fat; (b) improving the glucose tolerance of the patient; (c) increasing the sensitivity of the patient to insulin; (d) treating, relieving and preventing liver injury; (e) treating, relieving and preventing non-alcoholic steatohepatitis; (f) fat deposition caused by high-fat and high-cholesterol diet is reduced; (g) reducing blood fat; and / or (h) improving the level of at least one of the following indexes in the liver of the mammal: total cholesterol, triglyceride, low density lipoprotein-cholesterol and free fatty acid.

The invention discloses application of a group of blood nutrition markers in prediction of central nervous system (CNS) injury function prognosis. According to the technical scheme, the method is characterized in that serum albumin, total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) are determined as independent predictive factors of CNS injury prognosis for the first time through retrospective queue research (n = 404), and clinical decision critical values are determined to be 36.35 g / L, 3.60 mmol / L and 2.13 mmol / L respectively. The detection kit developed on the basis of the discovery can objectively and quantitatively evaluate the prognosis risk of the patient within 24 hours of admission, and is obviously superior to that of a traditional scoring system. According to the method, key technical support is provided for precise nutrition intervention and early rehabilitation strategy formulation of the CNS injury.

The disclosure provides methods of treating heterozygous familial hypercholesterolemia (HeFH) and / or atherosclerotic cardiovascular disease (ASCVD), more particularly in subjects who require additional lowering of low-density lipoprotein cholesterol (LDL-C). The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising obicetrapib or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

This invention discloses a *Lactobacillus plantarum* YBE2 and its applications. The *Lactobacillus plantarum* provided by this invention, which produces a high amount of extracellular polysaccharides primarily composed of rhamnose, can simultaneously degrade different types of bile salts, including specifically hydrolyzing glycocholic acid. It also exhibits cholesterol-lowering and acute inflammation-relieving effects. Furthermore, *Lactobacillus plantarum* YBE2 can reduce fat deposition in the abdomen of caged broilers, increase intramuscular fat, promote fatty acid deposition in muscles, and reduce plasma total bile acids, triglycerides, and low-density lipoprotein cholesterol. This significantly improves lipid metabolism and muscle quality in poultry, and can be widely applied in caged broiler farming to promote healthy poultry farming and improve farming efficiency.

This invention relates to a traditional Chinese medicine composition, specifically a traditional Chinese medicine composition for treating diabetic nephropathy, belonging to the fields of medicine and health products. The traditional Chinese medicine composition of this invention is made from components comprising the following raw materials: yam, salvia miltiorrhiza, rosehip, turtle shell, cornus officinalis, dioscorea hypoglauca, cuscuta chinensis, oyster shell, and American ginseng. Through rational formulation, this traditional Chinese medicine composition utilizes the principle of clearing heat and removing dampness, with the synergistic effect of multiple drugs, to significantly reduce fasting blood glucose, improve glucose metabolism, lower low-density lipoprotein cholesterol and triglycerides, and raise high-density lipoprotein cholesterol to regulate lipid metabolism, reduce weight, and has no significant damage to liver and kidney function, with minimal side effects.

A polyhydroxyalkanoate (PHA) containing monomer units of 3-hydroxybutyrate for use, by oral administration, in the prevention or treatment of an overweight or obesity condition, or of metabolic dysfunctions related to the condition. A marked effect was observed on the reduction of the body weight, both in the case of a standard diet and in the case of a diet rich in fats, a reduction that can be attributed to an increase in lipid oxidation to the detriment of the deposit of excess lipids, as confirmed by the decrease in the body weight and by analyses of the body composition. A positive effect on the metabolic dysfunctions related to an overweight or obesity condition has also been verified, in particular on dyslipidemias, such as the blood level of low-density lipoproteins (LDL cholesterol) and triglycerides, as well as an improvement in the inflammatory state.

The invention discloses compound safflower tea capable of reducing blood lipid. The compound safflower tea consists of the following components: 0.19 to 0.21 g of safflower, 0.195 to 2.050 g of American ginseng, 0.90 to 1.10 g of green tea, 1.10 to 1.20 g of hawthorn and 1.35 to 1.45 g of lotus leaf. According to the present invention, the C57BL / 6J mouse is subjected to the lipid-lowering experiment by using the safflower as the main material and using the American ginseng, the green tea, the hawthorn and the lotus leaf as the auxiliary materials, and the result shows that the safflower lipid-lowering tea can significantly reduce the levels of serum total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C), can improve the liver fatty degeneration and the inflammatory reaction, and can alleviate the intestinal injury caused by the high fat diet; animal behavior experiments including Y maze, open field experiments and new object recognition experiments are used to verify that the safflower lipid-lowering tea has an improvement effect on mouse cognitive impairment caused by dyslipidemia.

This invention discloses an oil composition with a balanced fatty acid ratio and lipid-lowering effects, and its applications. The oil composition comprises vegetable oil, probiotics, phospholipids from camellia seed cake, gelatin, and sodium alginate. It effectively reduces serum triglyceride, total cholesterol, and low-density lipoprotein cholesterol levels while increasing high-density lipoprotein cholesterol levels, exhibiting a good lipid-lowering effect. Furthermore, when the oil composition is formulated into microcapsules, it exhibits good stability, encapsulation efficiency, and release rate. The oil composition also helps maintain the activity of probiotics, allowing for better preservation and efficacy. Based on this, this invention also provides a candy containing the oil composition, enriching the variety of products with lipid-lowering effects and promoting the development of lipid-lowering related products.

The application discloses a polysaccharide composition for treating hyperlipidemia and application thereof, and belongs to the field of biological medicine. The polysaccharide composition is obtained by mixing Vansant yellow, Inonotus hispidus and Sarcodon fuligineus and then extracting with water. The polysaccharide composition can inhibit the increase of body weight and blood sugar of hyperlipidemia mice, reduce fat vacuolization and fat index, reduce the content of triglyceride, total cholesterol and low-density lipoprotein cholesterol in serum and increase the content of high-density lipoprotein cholesterol, and regulate the composition and abundance of intestinal flora to improve the intestinal flora disorder phenomenon, and the effect is better than that of single polysaccharide, thereby providing a new direction for the treatment of auxiliary blood sugar reduction.

Method of lowering low-density lipoprotein cholesterol or preventing a cardiac event in a subject who has atherosclerotic cardiovascular disease or who is atherosclerotic cardiovascular disease risk equivalent, involving administering to the subject a prophylactically effective amount of an RNAi agent. Also, a method of preventing development of atherosclerotic cardiovascular disease in a subject involving administering to the subject a prophylactically effective amount of an RNAi agent. Further, a method of treating a subject who has atherosclerotic cardiovascular disease or who is atherosclerotic cardiovascular disease risk equivalent involving administering to the subject a therapeutically effective amount of an RNAi agent.

This invention provides the use of RNA interferants that inhibit PCSK9 synthesis in prophylactic or therapeutic methods. [Solution] A method for reducing low-density lipoprotein cholesterol or preventing cardiac events in a subject having atherosclerotic cardiovascular disease or being at equivalent risk to atherosclerotic cardiovascular disease, comprising the step of administering a prophylactic effective amount of RNAi to the subject. Also, a method for preventing the onset of atherosclerotic cardiovascular disease in a subject, comprising the step of administering a prophylactic effective amount of RNAi to the subject. Furthermore, a method for treating a subject having atherosclerotic cardiovascular disease or being at equivalent risk to atherosclerotic cardiovascular disease, comprising the step of administering a therapeutic effective amount of RNAi to the subject.

This invention discloses the application of verbascoside in the preparation of drugs for treating obesity and related metabolic disorders, relating to the field of biopharmaceuticals. The drug upregulates the expression of phosphorylated AMP-activated protein kinase α and carnitine palmitoyltransferase-1α, while downregulating the expression of sterol regulatory element-binding protein-1c, fatty acid synthase, and acetyl-CoA carboxylase. This application is the first systematic study of the comprehensive intervention effect of verbascoside on diet-induced obesity and related metabolic disorders. In an in vivo obese mouse model, it was demonstrated that verbascoside can significantly inhibit excessive weight gain induced by a high-fat diet, reduce fasting blood glucose and fasting insulin levels, improve dyslipidemia indicators including triglycerides, total cholesterol, non-esterified fatty acids, and low-density lipoprotein cholesterol, enhance insulin sensitivity, and alleviate macrovesicular steatosis and hepatocellular damage.

This invention relates to compounds of Formula I and their isotopic forms, stereoisomers, tautomers, pharmaceutically acceptable salts, pharmaceutically acceptable solvates, hydrates, prodrugs, and polymorphs. The compounds of Formula I can be used as inhibitors of proprotein convertase subtilisin 9 (PCSK9), effectively inhibiting PCSK9 activity and reducing the concentration of low-density lipoprotein cholesterol in plasma, and have good application prospects in the preparation of drugs for the treatment or prevention of cardiovascular diseases.

The present application relates to a kind of fish oil polypeptide composition for reducing blood fat and its application, belong to the field of biological medicine and functional food.The composition includes fish oil and pumpkin seed source active peptide C2-1 (molecular weight <3kDa), wherein active peptide accounts for 1-5% of the total weight of composition.Its preparation method includes: pumpkin seed protein complex zymolysis, ultrafiltration separation, anion exchange chromatography purification obtains C2-1 active peptide (KRGGRFL), then with fish oil homogenization into stable dispersion.The composition significantly reduces serum total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) by simultaneously inhibiting cholesterol esterase and lipase activity, and improves high-density lipoprotein cholesterol (HDL-C).Animal experiments show that its lipid-lowering effect is better than single fish oil, and is comparable to chemical drugs.The present application first realizes polypeptide-fish oil synergistic effect, provides safe and efficient new scheme for hyperlipidemia prevention and treatment.

The invention belongs to the technical field of medical chemistry, and particularly relates to a preparation method and application of eicosapentaenoic acid-2-(1H-indole-3-yl) ethyl ester. According to the preparation method of the eicosapentaenoic acid-2-(1H-indole-3-yl) ethyl ester, provided by the invention, 2-(3-indolyl) ethanol and eicosapentaenoic acid are used as raw materials, and lipase is added to react and synthesize the eicosapentaenoic acid-2-(1H-indole-3-yl) ethyl ester. The eicosapentaenoic acid-2-(1H-indole-3-yl) ethyl ester prepared by the preparation method disclosed by the invention has an excellent and comprehensive lipid-lowering effect, not only can effectively reduce the contents of triglyceride, total cholesterol and low-density lipoprotein cholesterol in serum, but also can effectively increase the level of high-density lipoprotein cholesterol. Meanwhile, the compound also has a strong direct blood vessel protection effect, can remarkably repair vascular endothelial dysfunction caused by high-fat diet and effectively recover endothelium-dependent vasodilatation capability, and is a safe and effective novel cardiovascular disease medicine.

The utility model relates to the technical field of kits, and discloses a low-density lipoprotein cholesterol detection kit which comprises a storage box, anti-collision sleeves are fixedly mounted at four corners of the storage box, at least two slots are formed in the inner edge of the storage box, an insertion plate is mounted on the storage box in an insertion manner through the slots, and the anti-collision sleeves are fixedly mounted on the insertion plate. A first storage rack and a second storage rack are arranged in the storage box, a first storage groove and a second storage groove are formed in the first storage rack and the second storage rack in a penetrating mode, and a first turning cover and a second turning cover are rotationally installed on the outer edge of the storage box. According to the low-density lipoprotein cholesterol detection kit, the first protruding blocks and the second protruding blocks on the inner side of the turning cover correspond to the first storage grooves and the second storage grooves in a one-to-one mode, when the turning cover is closed, the protruding blocks can tightly press bottle caps of reagent bottles, elastic buffering fixing is formed, and the reagent bottles can be prevented from shaking up and down in the transportation process; and the storage grooves I distributed at equal intervals and the storage grooves II with larger diameters can be respectively matched with small-dose reagent bottles and large-dose reagent bottles, so that the modularized storage of the detection kit is realized.

The utility model relates to the technical field of cholesterol detection kit, and disclose a kind of small and dense low-density lipoprotein cholesterol detection kit, including storage box, first placement component and second placement component, at least two storage grooves are set in the storage box, the first placement component and second placement component are placed in the storage box by storage groove, hinge is set at the outer side of storage box, the other end of hinge away from storage box is provided with top cover, the first placement component includes the placement groove being set in the placement frame. The small and dense low-density lipoprotein cholesterol detection kit, support seat is fixed to the both sides of hinge, when opening top cover, support top cover can keep the angle of inclination, avoid top cover after completely opening and storage box collision, anti -skid line increase the friction between support seat and table top, prevent storage box from sliding in operation, the front handle of storage box and the top handle of top cover form bidirectional gripping structure, the design of two handles, it is convenient for user to take better.

The invention provides application of SPPARMs in treatment of atherosclerosis, and belongs to the technical field of biological medicine. An ApoE gene knockout mouse is subjected to high-fat feeding to construct an atherosclerotic mouse model, THP-1 macrophages are exposed to oxidized low-density lipoprotein to construct a macrophage foaming model, INT131 is used for drug administration to an animal model and a cell model, and results show that INT131 can effectively relieve formation of atherosclerotic plaques, and can be used for treating atherosclerotic plaques. The content of AS mouse serum total cholesterol and low-density lipoprotein cholesterol is obviously reduced, and the content of high-density lipoprotein cholesterol is increased. In addition, INT131 can reduce intake of lipid in macrophages, promote cholesterol excretion and cholesterol metabolism, and inhibit formation of foam cells by inhibiting inflammatory response.

The invention provides a composition for assisting in reducing blood fat, reducing blood sugar and reducing body weight and a preparation method thereof, the composition comprises the following core components in percentage by weight: 8-12% of L-arabinose, 5-10% of freeze-dried natto powder, 3-6% of red yeast rice powder, 2-3% of earthworm protein, 1-3% of vitamin C and the balance of water. And a plurality of active ingredients such as selenium-enriched malt flour, vitamin C, soybean peptide, marine oligopeptide, corn oligopeptide and the like and pharmaceutically acceptable auxiliary materials are used as auxiliary materials. By optimizing the preparation process of the marine oligopeptide, the palatability of the product is effectively improved. Through scientific compatibility of the components, a synergistic effect is generated on multiple target points. Experiments show that the composition can significantly reduce the weight, body fat, serum total cholesterol, triglyceride, low-density lipoprotein cholesterol and fasting blood-glucose levels of model rats and improve fatty degeneration of livers. The product has definite efficacy and good taste, and is suitable for preparing health-care food for assisting in regulating blood fat, blood sugar and body weight.

This invention provides a ginger active ingredient composition and its application. The ginger active ingredient composition includes acetylated 12-gingerol, 8-gingereneol, and 10-gingereneol in a mass ratio of (1-3):2:(2-3). The ginger active ingredient composition of this invention can improve glucose tolerance, increase insulin sensitivity, reduce serum triglyceride, total cholesterol, and low-density lipoprotein cholesterol levels, increase high-density lipoprotein levels, reduce the activity of hepatic alanine aminotransferase and aspartate aminotransferase, improve the degree of hepatic fat vacuolar lesions, and reduce the content of lipid metabolism-related metabolites in obese individuals. Simultaneously, acetylation of 12-gingerol improves its lipid solubility, enhances cell membrane penetration, reduces oxidative degradation of phenolic hydroxyl groups, and improves stability. Furthermore, it releases free 12-gingerol after enzymatic hydrolysis, achieving a sustained-release effect.

The invention relates to application of an ESRRA gene expression inhibitor in preparation of medicines for preventing and treating atherosclerosis, and belongs to the field of biological medicines. In order to solve the problem that existing drugs cannot specifically regulate and control phenotypic changes of VSMCs in atherosclerosis, the invention provides application of an ESRRA gene expression inhibitor in preparation of drugs for preventing and treating atherosclerosis, and the ESRRA gene expression inhibitor is a small nucleic acid gene silencing preparation and / or a small molecule compound AM251. The ESRRA gene expression inhibitor provided by the invention can remarkably inhibit abnormal proliferation and migration behaviors of vascular smooth muscle cells, block pathological transformation of the vascular smooth muscle cells to synthetic phenotypes, and remarkably lower the expression level of PCSK9 protein in the liver, so that the concentration of low-density lipoprotein cholesterol in plasma is effectively reduced, formation and development of new plaques are inhibited, and the ESRRA gene expression inhibitor has a good application prospect. The method has the advantage of multi-target and multi-channel synergistic effect.

The utility model discloses a combined test reagent card for comprehensive blood lipid indexes. The combined test reagent card comprises a shell, and a quantitative sample adding module and a test strip which are arranged in the shell, the test strip comprises a bottom plate, and a sample pad, a detection pad and a sample absorption pad which are sequentially overlapped on the bottom plate; the blood fat indexes comprise four indexes of total cholesterol, triglyceride, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol; a detection line and a quality control line are arranged on the detection pad, the detection line is coated with specific capture antibodies aiming at the four indexes, and the quality control line is coated with haptens or antibodies capable of being combined with quality control detection antibodies aiming at the four indexes; the quantitative sample adding module is arranged corresponding to the sample pad and comprises a quantitative bin and a waste liquid bin which are communicated with each other, and flow guide fibers are arranged between the quantitative bin and the waste liquid bin. According to the utility model, the joint detection of four blood fat indexes can be realized, the cost consumption is reduced, and accurate sample adding can be realized under the condition that verified sample adding equipment and professional technicians are not needed.

The application discloses low-molecular-weight fucoidan and a preparation method and application thereof, and the low-molecular-weight fucoidan contains 52% to 65% polysaccharide, 32% to 47% sulfate, 0 to 2% glucuronic acid and 0 to 1% protein, and has an average molecular weight of 2.0 to 4.5 kDa. The low-molecular-weight fucoidan prepared by a specific extraction and separation degradation method can resist high-fat-induced obesity, including reducing the contents of fasting blood glucose, total cholesterol, triglyceride and low-density lipoprotein cholesterol, and promoting the relative abundance of obesity negatively correlated flora and inhibiting the relative abundance of obesity positively correlated flora, thereby preventing the development of obesity, and having great application prospect as a candidate drug for preventing and / or treating obesity.

The invention discloses a traditional Chinese medicine composition for treating diabetic nephropathy, which is prepared from the following raw materials in parts by weight: 25 to 35 parts of radix astragali seu hedysari, 2 to 4 parts of radix notoginseng, 10 to 14 parts of radix angelicae sinensis, 13 to 17 parts of radix rehmanniae and 8 to 12 parts of cortex moutan, preferably 30 parts of radix astragali seu hedysari, 3 parts of radix notoginseng, 12 parts of radix angelicae sinensis, 15 parts of radix rehmanniae and 10 parts of cortex moutan. The composition is prepared based on the pathogenesis of'deficiency of both qi and yin and stasis of kidney collaterals' and based on the therapeutic principles of tonifying qi, nourishing yin and activating blood circulation. Pharmacodynamic experiments show that the composition can significantly improve the renal function and reduce the ratio of urine protein to creatinine, serum creatinine and urea nitrogen; lipid metabolism is regulated, and triglyceride, total cholesterol and low-density lipoprotein cholesterol are reduced; the kidney structure can be protected, basilar membrane thickening and podocyte damage are relieved, and the fibrosis process is inhibited. The invention provides a multi-target, safe and effective treatment choice for diabetic nephropathy.

This invention relates to the field of functional product technology, and more particularly to a composition for assisting in lowering blood lipids and its application. The invention provides a composition comprising *Bifidobacterium animalis* subsp. *lactamase* MN-Gup, microalgae oil, and phytosterol esters. The composition of this invention can simultaneously and effectively reduce triglyceride and total cholesterol levels, particularly significantly reducing low-density lipoprotein cholesterol while increasing high-density lipoprotein cholesterol levels. Compared to each individual component, it exhibits significant advantages, demonstrating significant auxiliary lipid-lowering efficacy with good safety and industrial feasibility. This provides a basis for the development of auxiliary lipid-lowering products and offers a new intervention strategy for blood lipid health management.